- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00000916
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma
This study compares the safety and effectiveness of continuing your current anti-HIV medications to that of adding or switching some of your anti-HIV medications. It will follow the effect of these medication changes, including the addition of hydroxyurea (HU), on long-term viral suppression. Other medications which may be added include didanosine (ddI) and/or stavudine (d4T).
Patients receiving combination antiretroviral therapy with indinavir (IDV), zidovudine (ZDV)(or d4T) and lamivudine (3TC) show viral suppression for two years or more. Discontinuation of one or two of these drugs results in prompt loss of the viral suppression. Other studies show that addition of HU to some reverse transcriptase inhibitor treatments results in increased antiviral effects. This study will provide further information on the effect of adding HU to a treatment regimen with respect to long-term viral suppression.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Previous ACTG studies show that discontinuation of one or two of a three-drug regimen (IDV, ZDV, 3TC) leads to prompt loss of viral suppression in the plasma. In this trial, it will be determined whether adding hydroxyurea (HU) to a suppressive regimen increases long term viral suppression. Important safety information on the tolerance of HU regimen will be characterized in asymptomatic patients with viral suppression.
Patients are equally randomized to one of three arms and receive treatment as follows:Arm A: IDV plus ddI plus d4T plus HU placebo. Arm B: IDV plus ddI plus d4T plus HU. Arm C: IDV plus 3TC/ZDV (or d4T plus 3TC). Patients are monitored every 8 weeks with plasma HIV RNA levels and CD4 cell counts.
Undersøgelsestype
Tilmelding
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Alabama Therapeutics CRS
-
-
California
-
Palo Alto, California, Forenede Stater, 943055107
- Stanford CRS
-
San Diego, California, Forenede Stater, 921036325
- Ucsd, Avrc Crs
-
San Mateo, California, Forenede Stater, 943055107
- San Mateo County AIDS Program
-
Torrance, California, Forenede Stater, 90502
- Harbor-UCLA Med. Ctr. CRS
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80262
- University of Colorado Hospital CRS
-
-
Florida
-
Miami, Florida, Forenede Stater, 331361013
- Univ. of Miami AIDS CRS
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96816
- Univ. of Hawaii at Manoa, Leahi Hosp.
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University CRS
-
Chicago, Illinois, Forenede Stater, 60640
- Weiss Memorial Hosp.
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
-
Indianapolis, Indiana, Forenede Stater, 462025250
- Indiana Univ. School of Medicine, Wishard Memorial
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Univ. of Iowa Healthcare, Div. of Infectious Diseases
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70112
- Tulane Hemophilia Treatment Ctr.
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins Adult AIDS CRS
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital ACTG CRS
-
Boston, Massachusetts, Forenede Stater, 02215
- Beth Israel Deaconess Med. Ctr., ACTG CRS
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University of Minnesota, ACTU
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater
- Washington U CRS
-
Saint Louis, Missouri, Forenede Stater, 63112
- St. Louis ConnectCare, Infectious Diseases Clinic
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 681985130
- Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.
-
-
New York
-
New York, New York, Forenede Stater, 10016
- NY Univ. HIV/AIDS CRS
-
New York, New York, Forenede Stater, 10003
- Beth Israel Med. Ctr. (Mt. Sinai)
-
New York, New York, Forenede Stater
- Beth Israel Med. Ctr., ACTU
-
Rochester, New York, Forenede Stater, 14642
- Univ. of Rochester ACTG CRS
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 275997215
- Unc Aids Crs
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas HealthCare System, Carolinas Med. Ctr.
-
Greensboro, North Carolina, Forenede Stater, 27401
- Regional Center for Infectious Disease, Wendover Medical Center CRS
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 452670405
- Univ. of Cincinnati CRS
-
Cleveland, Ohio, Forenede Stater, 44106
- Case CRS
-
Cleveland, Ohio, Forenede Stater, 441091998
- MetroHealth CRS
-
Columbus, Ohio, Forenede Stater, 432101228
- The Ohio State Univ. AIDS CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- University of Washington AIDS CRS
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
You may be eligible for this study if you:
- Are 13 years or older.
- Have documented HIV-1 infection.
- Are currently receiving combined IDV, ZDV(or D4T), and 3TC for at least 6 consecutive months, resulting in HIV RNA less than 200 copies/ml and CD4 cell count greater than 200 cells/mm3.
- Had a CD4 count greater than 100 cells/mm3 before starting current anti-HIV therapy.
- Are of childbearing age and agree to practice abstinence or use of combined barrier and hormonal methods of birth control during and for 3 months after the study.
Exclusion Criteria
You will not be eligible for this study if you:
- Have taken various medications and have various laboratory results (see technical abstract).
- Have cancer requiring chemotherapy.
- Have an unexplained fever for 7 days or diarrhea for 15 days in the month before the start of the study.
- Had prior peripheral neuropathy or hepatitis.
- Recently underwent radiation, experimental, or infection therapy.
- Are pregnant or breastfeeding.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Collier A
- Studiestol: Havlir D; Richman D
- Studiestol: Tebas P
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- HIV-infektioner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Antimetabolitter
- Antineoplastiske midler
- Proteasehæmmere
- HIV-proteasehæmmere
- Virale proteasehæmmere
- Antisickling midler
- Lamivudin
- Zidovudin
- Stavudine
- Indinavir
- Hydroxyurinstof
- Didanosin
- Lamivudin, zidovudin lægemiddelkombination
Andre undersøgelses-id-numre
- A5025
- 10873 (Registry Identifier: DAIDS ES)
- ACTG A5025
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-infektioner
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universidad del DesarrolloAfsluttetHealthcare Associated InfectionChile
-
The University of Texas Health Science Center,...EurofinsAfsluttetOdontogen Deep Space Neck InfectionForenede Stater
-
Imelda Hospital, BonheidenAfsluttetHealthcare Associated InfectionBelgien
-
Centre Hospitalier Universitaire de NīmesRekrutteringÆldre | Healthcare Associated InfectionFrankrig
-
Centre Hospitalier Universitaire, AmiensAfsluttetHealthcare Associated Infection | IglerFrankrig
-
University of PennsylvaniaAfsluttetAntimikrobiel resistensForenede Stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentAfsluttetMenneskelig mikrobiomForenede Stater
-
Universidad Autonoma de Nuevo LeonUkendtSundhedsrelaterede infektioner
Kliniske forsøg med Indinavirsulfat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutteringLokalt avanceret malignt fast neoplasma | Metastatisk malignt fast neoplasmaForenede Stater
-
Children's Oncology GroupNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeNeoplasma i centralnervesystemet | Fast neoplasma | Tilbagevendende akut leukæmi | Refraktær akut leukæmi | Infantil fibrosarkomForenede Stater, Canada
-
Daiichi Sankyo, Inc.AfsluttetÅreforkalkning | Heterozygot familiær hyperkolesterolæmiForenede Stater, Det Forenede Kongerige, Spanien, Sydafrika, Israel, Canada, Holland, Norge, Sverige
-
University of Texas at AustinKonan Chemical ManufacturingRekruttering
-
Semmelweis University Heart and Vascular CenterUkendtCerebrovaskulær ulykke | Prostetisk hjerteklaptrombose | Funktionsfejl i proteseventilenUngarn
-
Istituto Superiore di SanitàAfsluttetKlassisk Kaposis sarkomItalien
-
MediciNovaAfsluttetKronisk obstruktiv lungesygdomForenede Stater
-
AstraZenecaAfsluttetSunde frivillige farmakokinetiske undersøgelserDet Forenede Kongerige
-
Tedec-Meiji Farma, S.A.Afsluttet
-
National Cancer Institute (NCI)AfsluttetHIV-infektioner | Erhvervet immundefektsyndromForenede Stater